Finance

Lists
Why is PHAT down 9.95%?
Dive Deeper
PHAT:NASDAQ
Phathom Pharmaceuticals Inc
$5.12
-9.95%
(-0.57) 1D
Nov 5, 3:48:41 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHAT...
Open
$5.70
High
$5.70
Low
$5.09
Mkt. cap
415.81M
Avg. vol.
1.65M
Volume
912.12K
52-wk high
$18.31
52-wk low
$5.02
EPS
-$1.03
Beta
0.69
Shares outstanding
81.29M
No. of employees
371
Open
$5.70
High
$5.70
Low
$5.09
Mkt. cap
415.81M
Avg. vol.
1.65M
Volume
912.12K
52-wk high
$18.31
52-wk low
$5.02
EPS
-$1.03
Beta
0.69
Shares outstanding
81.29M
No. of employees
371
News stories
From web sources and news partners
About Phathom Pharmaceuticals Inc
CEO-
Employees371
Founded2018
HeadquartersFlorham Park, New Jersey, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitephathompharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to PHAT in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PHAT in the last 3 months.
Highest
Current $5.12
$26.00 (+408.31%)
Average
$16.90 (+230.40%)
Lowest
$7.50 (+46.63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Maintained
$7.50
+46.6%
11/02/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$22.00
+330.1%
10/29/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$26.00
+408.3%
10/30/2026
Jenna Davidner
Barclays
Buy
Maintained
$14.00
+173.7%
10/30/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
-
-
10/23/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
$15.00
+193.3%
10/21/2026
Martin Auster
Raymond James
Buy
Maintained
$21.00
+310.6%
07/31/2026
Joseph Stringer
Needham
Buy
Maintained
$22.00
+330.1%
07/30/2026
Paul Choi
Goldman Sachs
Hold
Maintained
-
-
04/30/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$0.04 / $0.03
+39.86%beat
Revenue / Est. (USD)
84.72M / 84.82M
-0.12%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
57.58M
58.30M
74.27M
84.72M
Cost of goods sold
7.65M
12.00M
15.10M
18.37M
Cost of revenue
7.65M
12.00M
15.10M
18.37M
Research and development expenses
7.49M
7.77M
7.81M
8.74M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
48.37M
54.01M
55.33M
57.70M
Operating expense
55.86M
61.78M
63.14M
66.44M
Total operating expenses
63.51M
73.78M
78.24M
84.81M
Operating income
-5.93M
-15.48M
-3.96M
-85.00K
Other non operating income
-5.00K
-831.00K
-24.00K
-25.00K
EBT including unusual items
-21.15M
-30.37M
-17.58M
-13.90M
EBT excluding unusual items
-21.15M
-30.37M
-17.58M
-13.90M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21.15M
-30.37M
-17.58M
-13.90M
Net profit margin
-36.73%
-52.09%
-23.67%
-16.40%
Earnings per share
-0.08
-0.18
-
0.04
Interest and investment income
1.20M
1.74M
1.51M
1.60M
Interest expense
-16.42M
-15.80M
-15.10M
-15.39M
Net interest expenses
-15.22M
-14.06M
-13.59M
-13.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.80M
-15.37M
-3.85M
35.00K
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps